(1)(1)(1).jpg)
The NAMIC under Haichang Biotech is dedicated to the research and development of innovative nucleic acid therapeutics. NAMIC aims to expand the applications of QTsome™, our proprietary lipid nanoparticle (LNP) delivery technology, across various nucleic acid therapeutics, and to cultivate a world-class platform for mRNA therapeutic delivery systems.
In our pursuit of a comprehensive strategy to mRNA therapy, NAMIC hones in on the design, synthesis, optimization, and delivery of nucleic acid therapeutics. This allows us to leverage the entire product lifecycle, from upstream to downstream processes. Innovation forms the core of NAMIC, and we are committed to creating a globally connected network that encapsulates complementary advantages, seamless integration, and adherence to internationally-recognized standards.
NAMIC consists of:
.png)
Division of mRNA Drug Substance Research (DMDSR)
.png)
Division of mRNA Drug Product Research (DMDPR)
.png)
Division of Small RNA Research (DSRR)
Division of Product Formulation Research (DPFR)
.png)
Division of Pharmaceutics Analysis (DPA)
We are a hub of brilliant minds. At NAMIC, we have gathered outstanding talents around the world to drive research. This global vision and focus on top-notch mind have helped us to become a leading research institute, frequently achieving technical breakthroughs in nucleic acid drug development.
As we navigate the ever-evolving world of biomedical research, NAMIC remains devoted to expanding its global presence. Our continuous efforts are to deliver top-quality health products for everyone, everywhere.
Design, synthesis, modification, and optimization of nucleic acid sequences
Design, synthesis, modification, and optimization of nucleic acid sequences
Synthesis, modification, and optimization of lipid components
Synthesis, modification, and optimization of lipid components
Optimization and upgrading of QTsomeTM
Optimization and upgrading of QTsomeTM
Transformation and commercial production of nucleic acid drugs
Transformation and commercial production of nucleic acid drugs
